相关实验视频

Updated: May 22, 2025

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

通过纳米益生菌复合物和IL-32调制,克服结直肠癌中免疫疗法耐药性

Shiquan Li¹, Tao Liu¹, Chenyao Li¹

¹Department of Colorectal & Anal Surgery, General Surgery Center, First Hospital of Jilin University, Changchun, 130021, China.

|March 13, 2025

概括

这项研究介绍了一种新的纳米生物材料SeNVs@NE-IL32-EcN,可以增强CD8+T细胞免疫力. 这种方法通过增强免疫反应,有效地克服了对结直肠癌免疫疗法的抵抗力.

科学领域:

免疫学免疫学免疫学
纳米技术纳米技术
微生物学微生物学

背景情况:

结肠直肠癌 (CRC) 是一个重大的全球健康挑战.
对于CRC的免疫疗法经常受到免疫耐受性和耐药性的阻碍.
CD8+ T 细胞在抗瘤免疫力中起着至关重要的作用.

研究的目的:

开发一种创新的纳米生物材料策略,以增强CD8+ T细胞介导的抗CRC免疫力.
在结直肠癌中克服免疫疗法耐药性.
为了研究纳米颗粒载荷细胞外囊的治疗潜力,结合Interleukin-32和工程益生菌Escherichia coli Nissle 1917 (SeNVs@NE-IL32-EcN).

主要方法:

单细胞RNA测序 (scRNA-seq) 和转录组分析确定了关键的免疫调节者.
用一个人性化的异种移植小鼠模型来评估治疗疗效.
SeNVs@NE-IL32-EcN被合成并根据形态,大小,抗氧化活性和安全性进行表征.

主要成果:

在免疫治疗耐药的CRC中观察到减少了CD8+ T细胞透.
鉴定出干白素-32 (IL32) 是一种关键的调节剂,增强了CD8+ T细胞的细胞毒性活性.
在体内,SeNVs@NE-IL32-EcN治疗显著改善了CD8+ T细胞活性,并减少了瘤进展,证明了生物相容性和抗氧化特性.

结论:

SeNVs@NE-IL32-EcN代表了一种新的纳米生物材料战略,将纳米技术和益生菌疗法整合在一起.
这种方法增强了CD8+ T细胞介导的免疫力,并克服了CRC免疫疗法耐药性.
这项研究为在癌症治疗中推进免疫调节生物材料提供了基础.

关键词:

生物材料疗法是一种生物材料疗法.CD8 (((+) T细胞是T细胞中的一个.结肠直肠癌是一种癌症.工程设计的益生菌.细胞外囊泡中的细胞外囊泡.IL32 IL32 是一个类型.免疫疗法耐药性免疫疗法耐药性纳米是一种.瘤微环境是一个微环境.

更多相关视频

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model

Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model

Published on: November 26, 2010

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...